Oncology Reviews最新文献_第9页

Periodontitis and oral cancer - current concepts of the etiopathogenesis. 牙周炎和口腔癌--目前的发病机制概念。

IF 3.6

Oncology Reviews Pub Date : 2020-03-18 eCollection Date: 2020-02-18 DOI: 10.4081/oncol.2020.465

Soussan Irani, Iman Barati, Mohammadreza Badiei

引用次数: 0

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review. 替莫唑胺延长辅助治疗对新诊断的多形性胶质母细胞瘤的影响:荟萃分析和系统评价。

IF 3.6

Oncology Reviews Pub Date : 2020-02-18 DOI: 10.4081/oncol.2020.461

Ehsan Alimohammadi, Seyed Reza Bagheri, Shahram Taheri, Maliheh Dayani, Alireza Abdi

{"title":"The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review.","authors":"Ehsan Alimohammadi, Seyed Reza Bagheri, Shahram Taheri, Maliheh Dayani, Alireza Abdi","doi":"10.4081/oncol.2020.461","DOIUrl":"https://doi.org/10.4081/oncol.2020.461","url":null,"abstract":"Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy is the current standard treatment for glioblastoma multiforme (GBM). The present metaanalysis investigated the impact of prolonged TMZ maintenance therapy (more than 6 cycles) in comparison with standard TMZ maintenance therapy (exactly six cycles) on overall survival (OS) and progression-free survival (PFS) of patients with GBM. A meta-analysis of the literature was conducted using Medline, PubMed, EMBASE and the Cochrane Library in accordance with PRISMA guidelines. Seven articles involving 1018 patients were included. The overall survival was higher in the case group (>6 cycles TMZ) compared to the control group (6 cycles TMZ) (Z=2.375, P=0.018). The lower and upper limits were between 1.002-10.467 months. The case group had higher progression-free survival compared with the control group (Z=3.84; P<0.001). The lower and upper limits were between 2.559-7.894 months. Evidence from this meta-analysis suggests that prolonged TMZ therapy compared to the standard 6-cycle TMZ therapy was associated with higher survival in patients with glioblastoma.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2020.461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37721399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

The biological mechanism involved in anticancer properties of amniotic membrane. 羊膜抗癌特性的生物学机制。

IF 3.6

Oncology Reviews Pub Date : 2020-02-18 DOI: 10.4081/oncol.2020.429

Ameneh Jafari, Hassan Niknejad, Mostafa Rezaei-Tavirani, Hakimeh Zali

引用次数: 4

Mitotic quiescence in hepatic cancer stem cells: An incognito mode. 肝癌干细胞有丝分裂静止:一种不可见的模式。

IF 3.6

Oncology Reviews Pub Date : 2020-02-18 DOI: 10.4081/oncol.2020.452

Kandasamy Ashokachakkaravarthy, Biju Pottakkat

引用次数: 4

Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. 黑色素瘤中阳性区域淋巴结的演变管理:过去，现在和未来的方向。

IF 3.6

Oncology Reviews Pub Date : 2019-11-28 eCollection Date: 2019-07-22 DOI: 10.4081/oncol.2019.433

Rachel A Fayne, Francisco I Macedo, Steven E Rodgers, Mecker G Möller

引用次数: 10

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. 雷帕霉素抑制剂对哺乳动物的肾毒性:随机临床试验的荟萃分析。

IF 3.6

Oncology Reviews Pub Date : 2019-11-25 eCollection Date: 2019-07-22 DOI: 10.4081/oncol.2019.455

Ravi K Paluri, Guru Sonpavde, Charity Morgan, Jacob Rojymon, Anastasia Hartzes Mar, Radhika Gangaraju

引用次数: 8

Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. 程序性细胞死亡-1/程序性细胞凋亡配体-1抑制剂治疗癌症三阴性乳腺癌的疗效和安全性：一项全面的系统综述。

IF 3.6

Oncology Reviews Pub Date : 2019-10-10 eCollection Date: 2019-07-22 DOI: 10.4081/oncol.2019.425

Gilbert Lazarus, Jessica Audrey, Anthony William Brian Iskandar

{"title":"Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.","authors":"Gilbert Lazarus, Jessica Audrey, Anthony William Brian Iskandar","doi":"10.4081/oncol.2019.425","DOIUrl":"10.4081/oncol.2019.425","url":null,"abstract":"Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PDL1 for TNBC from inception until February 2019. Risk of bias was assessed by the Newcastle-Ottawa Scale (NOS). Overall, 7 studies evaluating outcomes of 1395 patients with TNBC were included in this systematic review. Anti-PD-1/PD-L1 showed significant antitumor effect, proven by their promising response (objective response rate (ORR), 18.5-39.4%) and survival rates (median overall survival (OS), 9.2-21.3 months). Moreover, anti- PD-1/PD-L1 yielded better outcomes when given as first-line therapy, and overexpression of PD-L1 in tumors showed better therapeutic effects. On the other hands, safety profiles were similar across agents and generally acceptable, with grade ≥3 treatment- related adverse effects (AEs) ranging from 9.5% to 15.6% and no new AEs were experienced by TNBC patients. Most grade ≥3 AEs are immune-mediated, which are manifested as neutropenia, fatigue, peripheral neuropathy, and anemia. PD-1/PD-L1 inhibitors showed promising efficacy and tolerable AEs, and thus may benefit TNBC patients. Further studies of randomized controlled trials with larger populations are needed to better confirm the potential of these agents.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.425","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37475357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Current promising treatment strategy for glioblastoma multiform: A review. 多形性胶质母细胞瘤目前有前景的治疗策略：综述。

IF 3.1

Oncology Reviews Pub Date : 2019-07-25 eCollection Date: 2019-07-22 DOI: 10.4081/oncol.2019.417

Sanjib Bahadur, Arvind Kumar Sahu, Pragya Baghel, Suman Saha

{"title":"Current promising treatment strategy for glioblastoma multiform: A review.","authors":"Sanjib Bahadur, Arvind Kumar Sahu, Pragya Baghel, Suman Saha","doi":"10.4081/oncol.2019.417","DOIUrl":"10.4081/oncol.2019.417","url":null,"abstract":"Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2019-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/85/onco-13-2-417.PMC6661528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41207882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis MCT4具有作为预后生物标志物的潜力——一项系统综述和荟萃分析

IF 3.6

Oncology Reviews Pub Date : 2019-07-22 DOI: 10.4081/oncol.2019.403

Arslaan Javaeed, S. Ghauri

{"title":"MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis","authors":"Arslaan Javaeed, S. Ghauri","doi":"10.4081/oncol.2019.403","DOIUrl":"https://doi.org/10.4081/oncol.2019.403","url":null,"abstract":"The role of several metabolic changes, such as hypoxia and acidosis, in the tumour environment has caught the attention of researchers in cancer progression and invasion. Lactate transport is one of the acidosis-enhancing processes that are mediated via monocarboxylate transporters (MCTs). We conducted a systematic review and meta-analysis to investigate the expression of two cancer-relevant MCTs (MCT1 and MCT4) and their potential prognostic significance in patients with metastasis of different types of cancer. Studies were included if they reported the number of metastatic tissue samples expressing either low or high levels of MCT1 and/or MCT4 or those revealing the hazard ratios (HRs) of the overall survival (OS) or disease-free survival (DFS) as prognostic indicators. During the period between 2010 and 2018, a total of 20 articles including 3831 patients (56.3% males) were identified. There was a significant association between MCT4 expression (high versus low) and lymph node metastasis [odds ratio (OR)=1.87, 95% confidence interval (CI)=1.10-3.17, P=0.02] and distant metastasis (OR=2.18, 95%CI=1.65-2.86, P<0.001) and the correlation remained significant for colorectal and hepatic cancer in subgroup analysis. For survival analysis, patients with shorter OS periods exhibited a higher MCT4 expression [hazard ratio (HR)=1.78, 95%CI=1.49-2.13, P<0.001], while DFS was shorter in patients with high MCT1 (HR=1.48, 95%CI=1.04-2.10, P=0.03) and MCT4 expression (HR=1.70, 95%CI=1.19-2.42, P=0.003) when compared to their counterparts with low expression levels. Future research studies should consider the pharmacologic inhibition of MCT4 to effectively inhibit cancer progression to metastasis.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.403","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41966914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Recent trends in predictive biomarkers for determining malignant potential of oral potentially malignant disorders 预测口腔潜在恶性疾病的恶性潜能的生物标志物的最新趋势

IF 3.6

Oncology Reviews Pub Date : 2019-07-22 DOI: 10.4081/oncol.2019.424

G. Sarode, S. Sarode, Nikunj Maniyar, N. Sharma, Sujata Yerwadekar, S. Patil

{"title":"Recent trends in predictive biomarkers for determining malignant potential of oral potentially malignant disorders","authors":"G. Sarode, S. Sarode, Nikunj Maniyar, N. Sharma, Sujata Yerwadekar, S. Patil","doi":"10.4081/oncol.2019.424","DOIUrl":"https://doi.org/10.4081/oncol.2019.424","url":null,"abstract":"Despite of the tremendous advancements in the field of cancer prevention, detection and treatment, the overall prognosis of oral squamous cell carcinoma (OSCC) still remains poor. This can be partly imparted to the lack of early detection of oral potentially malignant disorders (OPMDs), especially those at a higher risk of progression into OSCC. Over years, various specific and non-specific markers have been introduced that could predict the malignant transformation of OPMDs; however detail information on these OPMD markers in a concise manner is lacking. Moreover, their use on daily clinical basis still remains questionable. With continuous research in the field of cytology and genomics, several contemporary biomarkers have been discovered that are not yet foregrounded and proved to be more promising than those used conventionally. Here, in the present paper, we overview several recently concluded predictive biomarkers with special emphasis on their role in molecular pathogenesis of OSCC transformation. These markers can be used for risk assessment of malignant transformation in patients with OPMDs as well as for prophylactic conciliation and fair management of the high-risk OPMD patient group.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2019-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.424","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42567484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13